Literature DB >> 30159691

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice.

Katsuyuki Hotta1,2, Kiichiro Ninomiya3, Eiki Ichihara3, Katsuyuki Kiura3.   

Abstract

The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.

Entities:  

Keywords:  Lung cancer; Re-biopsy; Treatment

Mesh:

Substances:

Year:  2018        PMID: 30159691     DOI: 10.1007/s10147-018-1344-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  2 in total

1.  First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.

Authors:  Kenichiro Kudo; Kazuya Nishii; Go Makimoto; Nobuhisa Ishikawa; Yukari Tsubata; Masahiro Kodani; Nobukazu Fujimoto; Masahiro Yamasaki; Tetsuya Kubota; Nagio Takigawa; Kazunori Fujitaka; Nobuhiro Kanaji; Takuo Shibayama; Junko Itano; Chihiro Ando; Katsuyuki Hotta; Katsuyuki Kiura
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-06       Impact factor: 4.322

2.  Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment.

Authors:  Malene Støchkel Frank; Uffe Bodtger; Julie Gehl; Lise Barlebo Ahlborn
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.